Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM. It blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis, and psoriasis.
Purity:
95.00%
CAS Number:
[1143503-69-8]
Target:
IL Receptor|||Interleukin
T38105
* VAT and and shipping costs not included. Errors and price changes excepted